Prolonged Subcutaneous Administration of Oxytocin Accelerates Angiotensin II-Induced Hypertension and Renal Damage in Male Rats

PLoS One. 2015 Sep 22;10(9):e0138048. doi: 10.1371/journal.pone.0138048. eCollection 2015.

Abstract

Oxytocin and its receptor are synthesised in the heart and blood vessels but effects of chronic activation of this peripheral oxytocinergic system on cardiovascular function are not known. In acute studies, systemic administration of low dose oxytocin exerted a protective, preconditioning effect in experimental models of myocardial ischemia and infarction. In this study, we investigated the effects of chronic administration of low dose oxytocin following angiotensin II-induced hypertension, cardiac hypertrophy and renal damage. Angiotensin II (40 μg/Kg/h) only, oxytocin only (20 or 100 ng/Kg/h), or angiotensin II combined with oxytocin (20 or 100 ng/Kg/h) were infused subcutaneously in adult male Sprague-Dawley rats for 28 days. At day 7, oxytocin or angiotensin-II only did not change hemodynamic parameters, but animals that received a combination of oxytocin and angiotensin-II had significantly elevated systolic, diastolic and mean arterial pressure compared to controls (P < 0.01). Hemodynamic changes were accompanied by significant left ventricular cardiac hypertrophy and renal damage at day 28 in animals treated with angiotensin II (P < 0.05) or both oxytocin and angiotensin II, compared to controls (P < 0.01). Prolonged oxytocin administration did not affect plasma concentrations of renin and atrial natriuretic peptide, but was associated with the activation of calcium-dependent protein phosphatase calcineurin, a canonical signalling mechanism in pressure overload-induced cardiovascular disease. These data demonstrate that oxytocin accelerated angiotensin-II induced hypertension and end-organ renal damage, suggesting caution should be exercised in the chronic use of oxytocin in individuals with hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / adverse effects*
  • Animals
  • Atrial Natriuretic Factor / blood
  • Calcineurin / metabolism
  • Cardiomegaly / chemically induced*
  • Hypertension / chemically induced*
  • Injections, Subcutaneous
  • Kidney / drug effects*
  • Kidney / pathology
  • Male
  • Oxytocin / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Renin / blood

Substances

  • Angiotensin II
  • Oxytocin
  • Atrial Natriuretic Factor
  • Calcineurin
  • Renin

Grants and funding

This work was supported by a research grant (2140-12005-0130 to RK & LC) from the Australian Institute of Tropical Health and Medicine, and James Cook University. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.